Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Chronic Obstructive Pulmonary Disease-I: Introduction01:20

Chronic Obstructive Pulmonary Disease-I: Introduction

2.8K
Chronic Obstructive Pulmonary Disease (COPD) is a long-lasting respiratory condition requiring continuous attention and care. It is a progressive lung disease that leads to breathing challenges due to airflow obstruction. It manifests as persistent respiratory symptoms and restricted airflow resulting from abnormalities in the airways and alveoli, usually due to long-term exposure to harmful particles or gases. COPD mainly consists of two primary conditions: emphysema and chronic bronchitis.
2.8K
Acute Respiratory Failure-II01:21

Acute Respiratory Failure-II

218
Type I Respiratory Failure, or hypoxemic respiratory failure, occurs when the partial pressure of oxygen (PaO2) in arterial blood falls below 60 mmHg while breathing room air without a corresponding increase in arterial carbon dioxide levels (PaCO2). This condition highlights a significant impairment in the lungs' capacity to oxygenate the blood.
The underlying physiological abnormalities that contribute to hypoxemic respiratory failure include:
218
Chronic Obstructive Pulmonary Disease-II: Pathophysiology01:20

Chronic Obstructive Pulmonary Disease-II: Pathophysiology

2.8K
Chronic Obstructive Pulmonary Disease (COPD) pathophysiology is intricate and multifaceted, involving a complex interplay of physiological processes. Understanding these mechanisms is crucial for effectively managing and treating COPD. Here is an in-depth look at the critical elements in the pathophysiology of COPD:
Chronic Inflammation
2.8K
Radiological Investigation II: MRI and Ventilation Perfusion Scan01:30

Radiological Investigation II: MRI and Ventilation Perfusion Scan

117
Description
Magnetic Resonance Imaging (MRI) and Ventilation Perfusion Scans are two radiological investigations that offer detailed diagnostic images of the body, particularly lung structures.
MRI
MRI uses magnetic fields and radiofrequency signals to distinguish between normal and abnormal tissues. This technology provides a more detailed diagnostic image than CT scans, enabling it to characterize pulmonary nodules, stage bronchogenic carcinoma, and evaluate inflammatory activity in...
117
Chronic Obstructive Pulmonary Disease-IV: Assessement and Diagnostic Studies01:27

Chronic Obstructive Pulmonary Disease-IV: Assessement and Diagnostic Studies

2.5K
Assessing and diagnosing Chronic Obstructive Pulmonary Disease (COPD) involves a detailed approach that includes a comprehensive review of medical history, physical examination, and a variety of diagnostic tests. This thorough evaluation is essential to ensure an accurate diagnosis and guide effective management strategies.
Medical History
2.5K
Pneumothorax-II01:27

Pneumothorax-II

141
Pneumothorax is a medical condition defined by the buildup of air in the pleural space between the lungs and the chest wall. This accumulation of air can lead to partial or complete lung collapse, resulting in a range of clinical manifestations. Understanding the clinical presentation and effective management strategies is crucial for healthcare professionals in providing timely and appropriate care to individuals with pneumothorax.
Clinical Manifestations:
141

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Genome-wide association study of Idiopathic Pulmonary Fibrosis susceptibility using clinically-curated European-ancestry datasets.

The European respiratory journal·2026
Same author

Deupirfenidone Compared with Pirfenidone and Placebo in Idiopathic Pulmonary Fibrosis (ELEVATE-IPF): a Phase 2b Randomized Placebo-Controlled Trial.

American journal of respiratory and critical care medicine·2026
Same author

Idiopathic pulmonary fibrosis risk loci in East Asian populations mirror those of European populations.

American journal of respiratory and critical care medicine·2026
Same author

A statistical model for lung function trajectory and mortality in patients with fibrotic interstitial lung disease.

American journal of respiratory and critical care medicine·2026
Same author

Cross-ancestry evaluation of idiopathic pulmonary fibrosis genetic risk variants.

medRxiv : the preprint server for health sciences·2026
Same author

Efficacy and safety of nerandomilast in patients with autoimmune disease-related progressive pulmonary fibrosis in the FIBRONEER-ILD trial.

Annals of the rheumatic diseases·2026

Related Experiment Video

Updated: Jun 28, 2025

Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease
04:44

Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease

Published on: June 16, 2020

19.9K

Interstitial Lung Disease: A Review.

Toby M Maher1,2

  • 1University of Southern California, Los Angeles.

JAMA
|April 22, 2024
PubMed
Summary
This summary is machine-generated.

Interstitial lung disease (ILD) affects 650,000 Americans, causing progressive dyspnea and respiratory failure. Treatments like antifibrotics, immunomodulators, and lung transplants offer improved survival and quality of life for ILD patients.

More Related Videos

Author Spotlight: Investigating the Key Factors of Obliterative Bronchiolitis After Lung Transplantation
06:15

Author Spotlight: Investigating the Key Factors of Obliterative Bronchiolitis After Lung Transplantation

Published on: November 10, 2023

868
A Standardized Method for Measuring Internal Lung Surface Area via Mouse Pneumonectomy and Prosthesis Implantation
08:46

A Standardized Method for Measuring Internal Lung Surface Area via Mouse Pneumonectomy and Prosthesis Implantation

Published on: July 26, 2017

13.2K

Related Experiment Videos

Last Updated: Jun 28, 2025

Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease
04:44

Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease

Published on: June 16, 2020

19.9K
Author Spotlight: Investigating the Key Factors of Obliterative Bronchiolitis After Lung Transplantation
06:15

Author Spotlight: Investigating the Key Factors of Obliterative Bronchiolitis After Lung Transplantation

Published on: November 10, 2023

868
A Standardized Method for Measuring Internal Lung Surface Area via Mouse Pneumonectomy and Prosthesis Implantation
08:46

A Standardized Method for Measuring Internal Lung Surface Area via Mouse Pneumonectomy and Prosthesis Implantation

Published on: July 26, 2017

13.2K

Area of Science:

  • Pulmonology
  • Internal Medicine
  • Medical Research

Background:

  • Interstitial lung disease (ILD) is a group of lung disorders causing inflammation and fibrosis, leading to progressive dyspnea and respiratory failure.
  • ILD affects approximately 650,000 individuals in the US, resulting in 25,000-30,000 deaths annually.
  • Common ILD types include idiopathic pulmonary fibrosis (IPF), hypersensitivity pneumonitis, and connective tissue disease-associated ILD.

Purpose of the Study:

  • To summarize current understanding and treatment approaches for Interstitial Lung Disease (ILD).
  • To highlight the impact of ILD on patient health and survival.
  • To review diagnostic methods and therapeutic interventions for various ILD subtypes.

Main Methods:

  • Review of existing literature on ILD epidemiology, diagnosis, and treatment.
  • Analysis of diagnostic accuracy for thoracic computed tomography in ILD subtypes.
  • Evaluation of prognostic indicators such as forced vital capacity (FVC) decline.
  • Assessment of therapeutic outcomes for antifibrotic, immunomodulatory, exercise, and oxygen therapies.
  • Review of lung transplant outcomes and management of pulmonary hypertension in end-stage ILD.

Main Results:

  • ILD presents with dyspnea on exertion, with cough reported in 30% of patients.
  • Thoracic CT shows high sensitivity (91%) and specificity (71%) for diagnosing ILD subtypes like IPF.
  • A 5% decline in FVC over 12 months doubles mortality risk.
  • Antifibrotic therapies (nintedanib, pirfenidone) slow FVC decline by 44-57% in IPF and progressive fibrotic ILD.
  • Immunomodulatory therapies can stabilize or improve FVC in CTD-associated ILD.
  • Structured exercise and oxygen therapy improve symptoms and quality of life.
  • Lung transplant offers improved survival (5.2-6.7 years) compared to no transplant (<2 years) for end-stage ILD.
  • Inhaled treprostinil improves symptoms in ILD patients with pulmonary hypertension.

Conclusions:

  • ILD requires timely diagnosis and management to mitigate progressive dyspnea and respiratory failure.
  • First-line treatments include nintedanib/pirfenidone for IPF and mycophenolate mofetil for CTD-ILD.
  • Lung transplant is a crucial option for advanced ILD patients.
  • Exercise training enhances functional capacity and quality of life in individuals with ILD.